Pacer Advisors Inc. decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,240,978 shares of the biotechnology company’s stock after selling 63,133 shares during the quarter. Pacer Advisors Inc.’s holdings in Exelixis were worth $54,392,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in the stock. Motiv8 Investments LLC acquired a new stake in Exelixis during the fourth quarter worth about $26,000. Anchor Investment Management LLC increased its stake in Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Acumen Wealth Advisors LLC acquired a new position in Exelixis in the 4th quarter valued at approximately $29,000. Activest Wealth Management acquired a new position in Exelixis in the 4th quarter valued at approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Exelixis by 1,380.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 773 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.
Exelixis Stock Performance
Shares of NASDAQ:EXEL opened at $51.91 on Friday. The company’s fifty day moving average is $48.81 and its 200-day moving average is $45.20. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $53.93. The company has a market capitalization of $13.05 billion, a PE ratio of 17.25, a P/E/G ratio of 1.50 and a beta of 0.41.
Analyst Ratings Changes
Several analysts have recently weighed in on EXEL shares. Barclays lifted their price objective on Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a report on Monday, April 20th. Wells Fargo & Company upped their target price on Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Stifel Nicolaus raised their target price on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, TD Cowen boosted their price target on shares of Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.35.
View Our Latest Report on EXEL
Insider Activity at Exelixis
In related news, EVP Dana Aftab sold 43,451 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares in the company, valued at $29,945,209.35. This represents a 6.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 32,110 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total value of $1,599,399.10. Following the sale, the executive vice president directly owned 357,638 shares of the company’s stock, valued at $17,813,948.78. This represents a 8.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 219,170 shares of company stock valued at $10,620,641. Insiders own 2.60% of the company’s stock.
About Exelixis
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
See Also
- Five stocks we like better than Exelixis
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
